Trial Profile
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2022
Price :
$35
*
At a glance
- Drugs Evofosfamide (Primary) ; Sunitinib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms SUNEVO; SUNINET
- 31 May 2020 Results of an exploratory analysis identifying somatic mutations associated with the clinical benefit of pNET patients treated with SUN+EVO combination presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 23 Mar 2020 Status changed from active, no longer recruiting to completed.
- 01 Feb 2020 This trial is complted(Global End Date: 10 Jan 2020), according to European Clinical Trials Database record.